SCHEMBL4332695

SCHEMBL4332695

O=C(Nc1ccc2cn[nH]c2c1)c1nc(Cc2cccnc2)n2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
FLT1 P17948 1/20 0.44
CLK2 P49760 2/20 0.43
CLK4 Q9HAZ1 2/20 0.43
MAP4K4 O95819 1/20 0.43
DYRK1A Q13627 1/20 0.43
SRPK1 Q96SB4 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CFTR P13569 1/20 0.42
PRKX P51817 1/20 0.42
CAMK2D Q13557 1/20 0.42
PKN2 Q16513 1/20 0.42
STK17A Q9UEE5 1/20 0.42
MAOB P27338 1/20 0.42
PARP1 P09874 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4320261 0.86 ATR (0.51) RAB9ANPC1SMN1; SMN2ALDH1A1CFTR
SCHEMBL4335813 0.85 PDE4A (0.52) RAB9ANPC1SMN1; SMN2HIF1APDE4A
SCHEMBL4329117 0.84 ROCK2 (0.44) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL4334597 0.83 PABPC1 (0.48) RAB9ANPC1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL4326402 0.83 NPC1 (0.51) NPC1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL13578008 0.78 ATR (0.38) RAB9AHPGDSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL4332310 0.78 ATR (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL4329012 0.78 IRAK4 (0.48) RAB9ANPC1SMN1; SMN2ALDH1A1MAOB
SCHEMBL4326784 0.78 PDE4A (0.51) RAB9ANPC1SMN1; SMN2HIF1APDE4A
SCHEMBL4322905 0.77 ATR (0.47) ALDH1A1HSD17B10KDM4EPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 RAB9A 1558/4885NPC1 1236/4885HPGD 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.